2008 new vision sensor: able to sense the pressure on the fundus
Variable Frequency Screw Air Compressor Screw Type Air Compressor,Variable Frequency Screw Compressor,Variable Frequency Screw Air Compressor,Variable Frequency Screw Type Air Compressor Ningbo Xinda Screw Compressor Co., Ltd. , https://www.augustcompressor.com
If the eye pressure is too high, the nerve fibers will die, resulting in loss of field of view or even blindness. Because intraocular pressure (glaucoma) usually has no pain, it is generally diagnosed late, and such patients often develop cataracts in old age.
In this case, the doctor usually removes the patient's lens and implants the artificial lens. In order to avoid further loss of nerve fibers, patients need to make the most accurate adjustment of intraocular pressure by drugs. Unfortunately, the pressure will change under the action of the drug, so the patient needs to check regularly and constantly adjust the dose.
A sensor invented by scientists at the Fraunhofer Microelectronic Circuits and Systems IMS Institute in Duisburg, Germany, enables patients to no longer need regular medical examinations. Thomasvanden Boom, director of the IMS Biomixing System, said: "We have implanted a 2.5x2.6mm sensor in the artificial lens. This will not damage the patient's vision."
The upper and lower parts of the sensor are made up of electrodes: the upper electrode is flexible and the lower part is harder. When the intraocular pressure rises, the upper electrode is pushed inward, reducing the distance between the electrodes, resulting in an increase in capacitance.
Using a tiny antenna, the sensor transmits pressure data to a special frame, and the patient can see through the auxiliary device whether the pressure data reaches a critical value. The antenna inside the glasses supplies the energy required by the sensor through an electromagnetic field. VandenBoom said: "Energy needs to be kept to a minimum, all components are only turned on when needed."
This technology is currently undergoing clinical testing and is expected to be operational within 2-3 years. In addition to use in the eye, it can also be implanted in the thigh or upper arm blood vessels to monitor high blood pressure and help patients with high intracranial pressure and incontinence.